Last updated: June 16, 2026
A BCMA × CD3 bispecific is an antibody with two distinct binding arms. One arm binds BCMA (B-cell maturation antigen, also known as TNFRSF17) — a cell-surface receptor highly expressed on plasma-cell-lineage tumor cells in multiple myeloma. The other arm binds CD3 on T cells. By tethering a T cell directly to a BCMA-expressing tumor cell, the bispecific redirects the patient's own immune system to attack the myeloma — an off-the-shelf, ready-now alternative to BCMA CAR-T (which requires leukapheresis and 3–6 weeks of cell manufacturing).
Why BCMA? BCMA is the most-validated plasma-cell-restricted target in MM after CD38. It is expressed on plasma cells (both malignant and normal), which makes it an effective target but also drives the patient-noticeable side-effect signal: depleting BCMA-expressing plasma cells causes profound hypogammaglobulinemia and a sustained risk of severe infection — the signal that distinguishes BCMA bispecifics from the GPRC5D class (talquetamab).
Administration. All three FDA-approved BCMA bispecifics are subcutaneous with cycle-1 step-up dosing (two priming doses several days apart, then the full treatment dose) to mitigate cytokine release syndrome. The FDA labels currently require inpatient hospitalization for the step-up doses; outpatient administration is being tested in multiple trials below.
| Drug | Sponsor | Target | FDA Status | Administration |
|---|---|---|---|---|
| Teclistamab (Tecvayli, JNJ-64007957) | Janssen Biotech / Johnson & Johnson | BCMA × CD3 | Accelerated approval October 25, 2022 (4+ prior lines RRMM, post anti-CD38 + PI + IMiD) | Subcutaneous, step-up dosing in cycle 1, inpatient required per label |
| Elranatamab (Elrexfio, PF-06863135) | Pfizer | BCMA × CD3 | Accelerated approval in 2023 (4+ prior lines RRMM, post anti-CD38 + PI + IMiD) — readers should check the current FDA prescribing information for the most up-to-date status | Subcutaneous, step-up dosing in cycle 1, inpatient required per label |
| Linvoseltamab (Lynozyfic, REGN5458) | Regeneron | BCMA × CD3 | Accelerated approval in 2024 (4+ prior lines RRMM, post anti-CD38 + PI + IMiD) — readers should check the current FDA prescribing information for the most up-to-date status | IV infusion (the only BCMA bispecific given IV rather than SubQ), step-up dosing in cycle 1, inpatient required per label |
| Cevostamab (RG6160) — related class, NOT BCMA | Genentech / Roche | FcRH5 × CD3 | Not yet FDA-approved. Phase 3 program in RRMM under way (NCT07555938) | IV infusion, step-up dosing |
Cevostamab is included on this page as a related — but distinct — class. Cevostamab targets FcRH5 (Fc receptor-like 5, also called FcRL5), not BCMA. We include it here because (a) it is the other plasma-cell-restricted CD3 bispecific in late-stage MM development, (b) it is one of the leading non-BCMA, non-GPRC5D sequencing options after BCMA failure, and (c) it shares the CD3-engaging class side-effect profile (CRS, ICANS) without the BCMA-specific infection-from-hypogammaglobulinemia burden. The page title makes the BCMA / FcRH5 distinction explicit.
Next-generation: JNJ-79635322 (BCMA × GPRC5D dual-bispecific). Janssen's JNJ-79635322 simultaneously engages both BCMA and GPRC5D on the tumor cell via two tumor-binding arms plus a CD3 arm — a dual-target strategy designed to reduce single-target antigen-escape resistance. The first Phase 3 head-to-head against teclistamab as the active comparator is open (NCT07518186). We include the JNJ-79635322 trial in this hub because it is structured around the BCMA bispecific class as the reference benchmark; talquetamab and etentamig (GPRC5D-only) are covered on the talquetamab page instead.
The reference benchmark. FDA accelerated approval Oct 25, 2022 on the MajesTEC-1 dataset. Largest Phase 3 program (MajesTEC-4 maintenance, MajesTEC-7 newly diagnosed, the Tal-Tec arm of NCT06208150, and head-to-head vs JNJ-79635322 in NCT07518186). Used as the active comparator in the first MM-bispecific head-to-head Phase 3.
Full teclistamab page → (25 recruiting trials in detail)
Pfizer's BCMA bispecific. The MagnetisMM program covers late-line single-agent (MagnetisMM-3 / NCT05020236 doublet with daratumumab in the Phase 3 expansion), post anti-CD38 + lenalidomide RRMM (MagnetisMM-32 / NCT06152575), and newly diagnosed transplant-ineligible MM (NCT05623020). MagnetisMM-30 (NCT06215118) combines elranatamab + iberdomide. Multiple maintenance trials (ElMMA NCT06931704 vs daratumumab maintenance; MRD-guided post-transplant NCT06483100; NCT06918002 post-D-VRd) and the ELDORADO Phase 2 (NCT07247097) vs daratumumab + RVd-lite in newly diagnosed transplant-ineligible MM.
25 recruiting trials in the ClinTrialFinder corpus (June 2026).
Regeneron's BCMA bispecific — the only BCMA bispecific currently given by IV infusion rather than subcutaneously. LINKER-MM-3 (NCT05730036) is the Phase 3 vs elotuzumab + pomalidomide + dexamethasone in RRMM; NCT06932562 is the Phase 3 vs standard of care in transplant-ineligible MM; NCT07393282 randomizes linvoseltamab vs daratumumab in high-risk smoldering MM (the most-watched early-intervention BCMA-bispecific Phase 3); NCT07222761 compares linvoseltamab monotherapy and linvoseltamab + carfilzomib vs standard combinations. Several novel-combination trials with REGN7945 (NCT06669247) and REGN17372 (NCT07455851), and a window-of-opportunity study in NDMM (NCT05828511).
15 recruiting trials in the ClinTrialFinder corpus (June 2026).
Genentech's FcRH5 × CD3 bispecific. Not yet FDA-approved. The Phase 3 NCT07555938 (cevostamab + pomalidomide + dexamethasone vs standard of care in previously treated MM) is the registrational trial. NCT05927571 combines cevostamab + elranatamab — the only trial co-administering two CD3 bispecifics with different tumor-binding arms (BCMA + FcRH5). NCT06934044 is the Chinese Phase 1.
3 recruiting MM trials in the ClinTrialFinder corpus (June 2026). Included here as a related-class sequencing option, not as a BCMA bispecific.
The 65 recruiting BCMA-bispecific trials below are grouped by the clinical setting most patients and hematologists ask about first — line of therapy + patient context. Each NCT links to ClinicalTrials.gov for current eligibility and study-site details.
The largest 2026 trend: moving BCMA bispecifics out of late-line RRMM into front-line transplant-ineligible MM. Four Phase 3 trials are open across the three approved BCMA bispecifics:
Phase 3 confirmatory trials that move BCMA bispecifics out of 4+ prior lines into 1–3 prior lines:
The FDA-approved setting (4+ prior lines, post anti-CD38 + PI + IMiD) and adjacent triple-class refractory combinations:
The 2026 frontier: moving BCMA bispecifics in before active MM in patients who would otherwise wait for organ damage:
The FDA label currently requires hospitalization for cycle-1 step-up doses — the main operational bottleneck for adoption in community oncology. Multiple BCMA-bispecific trials are working on outpatient administration:
AL amyloidosis is a plasma-cell-driven disease that also expresses BCMA — a major non-MM use case for BCMA bispecifics:
FcRH5 is a separate plasma-cell-restricted target. Cevostamab is not BCMA, but is the leading non-BCMA, non-GPRC5D CD3 bispecific in MM development — a sequencing option for patients whose disease has progressed on BCMA bispecifics:
Pipeline trials that are likely to open during the second half of 2026:
Showing 65 recruiting interventional BCMA × CD3 bispecific trials (teclistamab 25 + elranatamab 25 + linvoseltamab 15) and 3 recruiting cevostamab (FcRH5, related class) trials in the ClinTrialFinder corpus as of June 16, 2026. Not-yet-recruiting trials are listed separately. For the latest searches: teclistamab, elranatamab, linvoseltamab, cevostamab.
BCMA × CD3 is the largest CD3-engaging bispecific class in MM, but it is not the only one. When BCMA bispecifics fail or are not appropriate, the practical alternatives are:
Cross-trial efficacy comparisons between the three approved BCMA bispecifics — or between BCMA, GPRC5D, and FcRH5 — have not been validated in head-to-head randomized trials and should not be inferred from response-rate differences across separate single-arm studies. The choice of which bispecific or which target class is right for a specific patient is a discussion with the patient's hematologist.
BCMA bispecifics share the broader CD3-engaging bispecific class profile but carry a BCMA-specific signal that distinguishes them from the GPRC5D class:
By contrast, the GPRC5D bispecific talquetamab has its own patient-noticeable signal (dysgeusia / taste loss, skin changes, nail changes) reflecting where GPRC5D is normally expressed (keratinized tissues), but generally less severe infection burden than the BCMA class. Cevostamab (FcRH5) shares the CRS / ICANS class signal but does not deplete normal plasma cells as profoundly as BCMA, so the infection burden is typically less prominent (though pivotal datasets are still maturing).
What is BCMA × CD3 bispecific therapy?
A BCMA × CD3 bispecific is an antibody with two binding arms. One arm binds BCMA (B-cell maturation antigen) — a target highly expressed on plasma-cell-lineage tumor cells in multiple myeloma — and the other arm binds CD3 on T cells. By tethering a T cell directly to a BCMA-expressing tumor cell, the bispecific redirects the patient's own immune system to attack the myeloma. All three FDA-approved BCMA bispecifics (teclistamab / Tecvayli, elranatamab / Elrexfio, linvoseltamab / Lynozyfic) require cycle-1 step-up dosing to mitigate cytokine release syndrome (CRS); FDA labels currently require inpatient hospitalization for the step-up doses, and outpatient administration is being tested.
Which BCMA bispecific is best for my multiple myeloma?
There is no published randomized head-to-head trial of teclistamab vs elranatamab vs linvoseltamab in late-line RRMM. Cross-trial efficacy ranges look broadly similar, so the choice is best framed as options to discuss with your hematologist: insurance coverage, your transplant center's experience with each drug, dosing-interval preferences, route of administration (teclistamab and elranatamab are SubQ; linvoseltamab is IV), and which trial slots are open near you. The JNJ-79635322 Phase 3 (NCT07518186) is the first randomized head-to-head in MM bispecifics — using teclistamab as the active comparator vs the BCMA × GPRC5D dual-bispecific.
What is BCMA bispecific prep and administration like?
All three FDA-approved BCMA bispecifics use cycle-1 step-up dosing — two priming doses several days apart, then the full treatment dose — to reduce severe CRS risk. FDA labels currently require inpatient hospitalization for the cycle-1 step-up doses. After cycle 1, dosing transitions to weekly or every-other-week schedules depending on the drug. Prep includes premedications (steroids, antipyretics, antihistamines), IV hydration, and an infection-prophylaxis plan (IVIG, anti-PJP and antiviral prophylaxis). Teclistamab and elranatamab are subcutaneous injections; linvoseltamab is given by IV infusion. Self-administration at home and fully outpatient administration are being tested (NCT06015542, NCT06421675, NCT05972135, NCT06251076, NCT07637578, NCT07609940).
What are the main side effects of BCMA bispecifics?
The defining BCMA-bispecific signal is severe infection risk driven by hypogammaglobulinemia — BCMA is expressed on normal plasma cells as well as tumor cells, so engaging T cells against BCMA depletes the antibody-producing plasma cells, leading to very low IgG and a sustained risk of opportunistic infection. Prophylactic antimicrobials and IVIG replacement are typically part of supportive care. The class-shared CD3-engaging signals are cytokine release syndrome (CRS) (mostly Grade 1–2, cycle-1, managed with tocilizumab), immune effector cell-associated neurotoxicity syndrome (ICANS) (less frequent than with CAR-T, generally reversible), and cytopenias (neutropenia, anemia, thrombocytopenia). By contrast, the GPRC5D class (talquetamab) has dysgeusia / skin / nail changes as its patient-noticeable signal rather than the BCMA infection burden.
How do I access a BCMA bispecific clinical trial?
Use ClinTrialFinder's AI-powered matching to surface BCMA bispecific trials based on your specific situation — line of therapy, prior anti-CD38 / PI / IMiD exposure, transplant status, BCMA-prior exposure (most teclistamab and elranatamab trials require BCMA-naïve), and disease stage. Start from the patient-match button below; the wizard routes through teclistamab as the most-established BCMA bispecific entry point and will surface relevant elranatamab and linvoseltamab trials in the same setting. Patients who have already progressed on a BCMA bispecific or BCMA CAR-T should also see the talquetamab (GPRC5D) page for the non-BCMA sequencing class.
Find Matching BCMA Bispecific Trials
Use ClinTrialFinder's AI-powered matching to find teclistamab, elranatamab, linvoseltamab, and cevostamab trials based on your line of therapy, prior treatments, and disease stage.
Find Matching BCMA Bispecific TrialsThis page is for information only and is not medical advice. ClinTrialFinder helps you find clinical trials that may match your situation, but enrollment decisions and treatment choices should always be made with your oncologist or hematologist. Trial eligibility, recruitment status, and treatment details can change — verify directly with the trial sponsor or on ClinicalTrials.gov before acting on any information here. FDA approval dates and indications are summarized for context only; consult the current FDA prescribing information for each drug for authoritative regulatory status.